By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Adrenergic bronchodilators > Epinephrine inhalation > Epinephrine Dosage
Adrenergic bronchodilators
https://themeditary.com/dosage-information/epinephrine-dosage-10267.html

Epinephrine Dosage

Drug Detail:Epinephrine inhalation (Epinephrine inhalation [ ep-i-nef-rin ])

Drug Class: Adrenergic bronchodilators Catecholamines Vasopressors

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Asystole

Injectable Solution of 0.1 mg/mL (1:10,000):

  • IV: 0.5 to 1 mg (5 to 10 mL) IV once; during resuscitation effort, 0.5 mg (5 mL) should be given IV every 5 minutes
  • Intracardiac: 0.3 to 0.5 mg (3 to 5 mL) via intracardiac injection into left ventricular chamber once
  • Endotracheal: 0.5 to 1 mg (5 mL to 10 mL) via endotracheal tube directly into bronchial tree once

Comments:
  • Intracardiac injection should only be administered by personnel well trained in this technique and only if there has not been sufficient time to establish an IV route.

Use: For prophylaxis and treatment of cardiac arrest and attacks of transitory atrioventricular heart block with syncopal seizures (Stokes-Adams Syndrome)

The American Heart Association (AHA) recommends:
  • IV or intraosseous: 1 mg IV or intraosseous every 3 to 5 minutes during cardiac arrest
  • Endotracheal: 2 to 2.5 mg endotracheally every 3 to 5 minutes during cardiac arrest if IV or intraosseous route cannot be established

Use: For administration during cardiac arrest

Usual Adult Dose for Ventricular Fibrillation

Injectable Solution of 0.1 mg/mL (1:10,000):

  • IV: 0.5 to 1 mg (5 to 10 mL) IV once; during resuscitation effort, 0.5 mg (5 mL) should be given IV every 5 minutes
  • Intracardiac: 0.3 to 0.5 mg (3 to 5 mL) via intracardiac injection into left ventricular chamber once
  • Endotracheal: 0.5 to 1 mg (5 mL to 10 mL) via endotracheal tube directly into bronchial tree once

Comments:
  • Intracardiac injection should only be administered by personnel well trained in this technique and only if there has not been sufficient time to establish an IV route.

Use: For prophylaxis and treatment of cardiac arrest and attacks of transitory atrioventricular heart block with syncopal seizures (Stokes-Adams Syndrome)

The American Heart Association (AHA) recommends:
  • IV or intraosseous: 1 mg IV or intraosseous every 3 to 5 minutes during cardiac arrest
  • Endotracheal: 2 to 2.5 mg endotracheally every 3 to 5 minutes during cardiac arrest if IV or intraosseous route cannot be established

Use: For administration during cardiac arrest

Usual Adult Dose for Ventricular Tachycardia

Injectable Solution of 0.1 mg/mL (1:10,000):

  • IV: 0.5 to 1 mg (5 to 10 mL) IV once; during resuscitation effort, 0.5 mg (5 mL) should be given IV every 5 minutes
  • Intracardiac: 0.3 to 0.5 mg (3 to 5 mL) via intracardiac injection into left ventricular chamber once
  • Endotracheal: 0.5 to 1 mg (5 mL to 10 mL) via endotracheal tube directly into bronchial tree once

Comments:
  • Intracardiac injection should only be administered by personnel well trained in this technique and only if there has not been sufficient time to establish an IV route.

Use: For prophylaxis and treatment of cardiac arrest and attacks of transitory atrioventricular heart block with syncopal seizures (Stokes-Adams Syndrome)

The American Heart Association (AHA) recommends:
  • IV or intraosseous: 1 mg IV or intraosseous every 3 to 5 minutes during cardiac arrest
  • Endotracheal: 2 to 2.5 mg endotracheally every 3 to 5 minutes during cardiac arrest if IV or intraosseous route cannot be established

Use: For administration during cardiac arrest

Usual Adult Dose for Cardiac Arrest

Injectable Solution of 0.1 mg/mL (1:10,000):

  • IV: 0.5 to 1 mg (5 to 10 mL) IV once; during resuscitation effort, 0.5 mg (5 mL) should be given IV every 5 minutes
  • Intracardiac: 0.3 to 0.5 mg (3 to 5 mL) via intracardiac injection into left ventricular chamber once
  • Endotracheal: 0.5 to 1 mg (5 mL to 10 mL) via endotracheal tube directly into bronchial tree once

Comments:
  • Intracardiac injection should only be administered by personnel well trained in this technique and only if there has not been sufficient time to establish an IV route.

Use: For prophylaxis and treatment of cardiac arrest and attacks of transitory atrioventricular heart block with syncopal seizures (Stokes-Adams Syndrome)

The American Heart Association (AHA) recommends:
  • IV or intraosseous: 1 mg IV or intraosseous every 3 to 5 minutes during cardiac arrest
  • Endotracheal: 2 to 2.5 mg endotracheally every 3 to 5 minutes during cardiac arrest if IV or intraosseous route cannot be established

Use: For administration during cardiac arrest

Usual Adult Dose for Asthma - Acute

Injectable Solution of 0.1 mg/mL (1:10,000):
0.1 to 0.25 mg (1 to 2.5 mL) IV slowly once

Use: For the treatment of acute asthmatic attacks to relieve bronchospasm not controlled by inhalation or subcutaneous administration of other solutions of the drug

Usual Adult Dose for Allergic Reaction

Auto-Injector:
30 kg or greater: 0.3 mg IM or subcutaneously into anterolateral aspect of thigh; repeat as needed

Comments:

  • The manufacturer product information for the specific auto-injector being used should be consulted for administration instructions.
  • More than 2 sequential doses should only be administered under direct medical supervision.
  • The auto-injectors are intended for immediate administration as emergency supportive therapy only and not as a replacement or substitute for immediate medical care.

Injectable Solution of 1 mg/mL (1:1000):
30 kg or greater: 0.3 to 0.5 mg (0.3 to 0.5 mL) of undiluted drug IM or subcutaneously into anterolateral aspect of the thigh; repeat every 5 to 10 minutes as needed
  • Maximum dose per injection: 0.5 mg (0.5 mL)

Comments:
  • For IM administration, use a long enough needle (at least 1/2 inch to 5/8 inch) to ensure injection into the muscle.
  • Repeated injections should not be administered at the same site as resulting vasoconstriction may cause tissue necrosis.
  • The patient should be monitored clinically for reaction severity and cardiac effects with repeat doses titrated to effect.

Injectable Solution of 0.1 mg/mL (1:10,000):
0.1 to 0.25 mg (1 to 2.5 mL) IV slowly once

Convenience Kit 1 mg/mL (1:1000):
0.2 to 1 mg IM or subcutaneous

Uses: For the emergency treatment of allergic reactions (Type I) including anaphylaxis to stinging or biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis; and for immediate administration in patients who are determined to be at increased risk for anaphylaxis, including those with a history of anaphylactic reactions

Usual Adult Dose for Anaphylaxis

Auto-Injector:
30 kg or greater: 0.3 mg IM or subcutaneously into anterolateral aspect of thigh; repeat as needed

Comments:

  • The manufacturer product information for the specific auto-injector being used should be consulted for administration instructions.
  • More than 2 sequential doses should only be administered under direct medical supervision.
  • The auto-injectors are intended for immediate administration as emergency supportive therapy only and not as a replacement or substitute for immediate medical care.

Injectable Solution of 1 mg/mL (1:1000):
30 kg or greater: 0.3 to 0.5 mg (0.3 to 0.5 mL) of undiluted drug IM or subcutaneously into anterolateral aspect of the thigh; repeat every 5 to 10 minutes as needed
  • Maximum dose per injection: 0.5 mg (0.5 mL)

Comments:
  • For IM administration, use a long enough needle (at least 1/2 inch to 5/8 inch) to ensure injection into the muscle.
  • Repeated injections should not be administered at the same site as resulting vasoconstriction may cause tissue necrosis.
  • The patient should be monitored clinically for reaction severity and cardiac effects with repeat doses titrated to effect.

Injectable Solution of 0.1 mg/mL (1:10,000):
0.1 to 0.25 mg (1 to 2.5 mL) IV slowly once

Convenience Kit 1 mg/mL (1:1000):
0.2 to 1 mg IM or subcutaneous

Uses: For the emergency treatment of allergic reactions (Type I) including anaphylaxis to stinging or biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis; and for immediate administration in patients who are determined to be at increased risk for anaphylaxis, including those with a history of anaphylactic reactions

Usual Adult Dose for Pupillary Dilation

Injectable Solution of 1 mg/mL (1:1000):

  • Intraocular: Dilute 1 mL of the 1 mg/mL single-use vial (1:1000) in 100 to 1000 mL of an ophthalmic irrigation fluid to a concentration of 1:100,000 to 1:1,000,000 (10 mcg/mL to 1 mcg/mL) and use the irrigating solution as needed for the surgical procedure
  • Intracameral: Following dilution in an ophthalmic irrigating fluid, the solution may also be injected intracamerally as a bolus dose of 0.1 mL at a dilution of 1:100,000 to 1:400,000 (10 mcg/mL to 2.5 mcg/mL)

Comments:
  • The Adrenalin(R) formulation is not for ophthalmic use.
  • Do not use if the solution is colored, cloudy, or contains particulate matter.

Use: For the induction and maintenance of mydriasis during intraocular surgery

Usual Adult Dose for Hypotension

Injectable Solution of 1 mg/mL (1:1000): 0.05 to 2 mcg/kg/min IV and titrate to achieve desired mean arterial pressure (MAP)

  • Dosage may be adjusted periodically, such as every 10 to 15 minutes in increments of 0.05 to 0.2 mcg/kg/min to achieve desired blood pressure goal

Comments:
  • Must be diluted prior to use; consult manufacturer product information for appropriate dilution instructions.
  • Correct blood volume depletion as fully as possible prior to administration; may be administered before and concurrently with blood volume replacement as an emergency measure.
  • Continuous infusion is generally required over several hours or days until patient's hemodynamic status improves; the duration of perfusion or total cumulative dose cannot be known.
  • Following hemodynamic stabilization, may wean incrementally over time, such as decreasing doses every 30 minutes over a 12 to 24 hour period.

Use: To increase mean arterial blood pressure in patients with hypotension associated with septic shock

Usual Adult Dose for Shock

Injectable Solution of 1 mg/mL (1:1000): 0.05 to 2 mcg/kg/min IV and titrate to achieve desired mean arterial pressure (MAP)

  • Dosage may be adjusted periodically, such as every 10 to 15 minutes in increments of 0.05 to 0.2 mcg/kg/min to achieve desired blood pressure goal

Comments:
  • Must be diluted prior to use; consult manufacturer product information for appropriate dilution instructions.
  • Correct blood volume depletion as fully as possible prior to administration; may be administered before and concurrently with blood volume replacement as an emergency measure.
  • Continuous infusion is generally required over several hours or days until patient's hemodynamic status improves; the duration of perfusion or total cumulative dose cannot be known.
  • Following hemodynamic stabilization, may wean incrementally over time, such as decreasing doses every 30 minutes over a 12 to 24 hour period.

Use: To increase mean arterial blood pressure in patients with hypotension associated with septic shock

Usual Adult Dose for Bradyarrhythmia

The manufacturer gives no specific dosing instructions.

The AHA recommends:
2 to 10 mcg/min IV and titrate to patient response

  • Alternate dose: 0.1 to 0.5 mcg/kg/min (in a 70 kg patient, 7 to 35 mcg/min) IV; titrate to effect

Use: For patients with symptomatic bradycardia, particularly if associated with hypotension, for whom atropine may be inappropriate or after atropine fails

Usual Pediatric Dose for Cardiac Arrest

The manufacturer gives no specific dosing instructions.

The AHA recommends:
Neonates:

  • IV: 0.01 to 0.03 mg/kg (1:10,000 injectable solution) IV once
  • Endotracheal: 0.05 to 0.1 mg/kg (1:10,000 injectable solution) via endotracheal route once may be reasonable while attempting to gain IV access

Comments:
  • Due to lack of data to support endotracheal use, it is reasonable to provide medications via IV route as soon as venous access is established.

Infants and Children:
  • IV or intraosseous: 0.01 mg/kg (0.1 mL/kg of 1:10,000 injectable solution) IV or intraosseous once; may repeat every 3 to 5 minutes
  • Maximum dose: 1 mg

Endotracheal: 0.1 mg/kg (0.1 mL/kg of 1:1000 injectable solution) via endotracheal tube once, flush with 5 mL normal saline and follow with 5 ventilations; may repeat every 3 to 5 minutes
  • Maximum dose: 2.5 mg

Use: For resuscitation in the pediatric patient

Usual Pediatric Dose for Allergic Reaction

Auto-Injector:
7.5 to 15 kg: 0.1 mg IM or subcutaneously into anterolateral aspect of thigh; repeat as needed
15 to 30 kg: 0.15 mg IM or subcutaneously into anterolateral aspect of thigh; repeat as needed
30 kg or greater: 0.3 mg IM or subcutaneously into anterolateral aspect of thigh; repeat as needed

Comments:

  • Since the lowest dose of the auto-injector is 0.1 mg, consider using other injectable forms of this drug if doses lower than 0.1 mg are necessary.
  • More than 2 sequential doses should only be administered under direct medical supervision.
  • The manufacturer product information for the specific auto-injector being used should be consulted for administration instructions.

Injectable Solution of 1 mg/mL (1:1000):
Less than 30 kg: 0.01 mg/kg (0.01 mL/kg) of undiluted drug IM or subcutaneously into anterolateral aspect of thigh; repeat every 5 to 10 minutes as needed
  • Maximum dose per injection: 0.3 mg (0.3 mL)
30 kg or greater: 0.3 to 0.5 mg (0.3 to 0.5 mL) of undiluted drug IM or subcutaneously into anterolateral aspect of the thigh; repeat every 5 to 10 minutes as needed
  • Maximum dose per injection: 0.5 mg (0.5 mL)

Comments:
  • For IM administration, use a long enough needle (at least 1/2 inch to 5/8 inch) to ensure injection into the muscle.
  • Repeated injections should not be administered at the same site as resulting vasoconstriction may cause tissue necrosis.
  • The patient should be monitored clinically for reaction severity and cardiac effects with repeat doses titrated to effect.

Injectable Solution of 0.1 mg/mL (1:10,000):
  • Neonate: 0.01 mg/kg IV slowly once
  • Infant: 0.05 mg IV slowly once; may repeat at 20 to 30 minute intervals as needed

Uses: For the emergency treatment of allergic reactions (Type I) including anaphylaxis to stinging or biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis; and for immediate administration in patients who are determined to be at increased risk for anaphylaxis, including those with a history of anaphylactic reactions

Usual Pediatric Dose for Anaphylaxis

Auto-Injector:
7.5 to 15 kg: 0.1 mg IM or subcutaneously into anterolateral aspect of thigh; repeat as needed
15 to 30 kg: 0.15 mg IM or subcutaneously into anterolateral aspect of thigh; repeat as needed
30 kg or greater: 0.3 mg IM or subcutaneously into anterolateral aspect of thigh; repeat as needed

Comments:

  • Since the lowest dose of the auto-injector is 0.1 mg, consider using other injectable forms of this drug if doses lower than 0.1 mg are necessary.
  • More than 2 sequential doses should only be administered under direct medical supervision.
  • The manufacturer product information for the specific auto-injector being used should be consulted for administration instructions.

Injectable Solution of 1 mg/mL (1:1000):
Less than 30 kg: 0.01 mg/kg (0.01 mL/kg) of undiluted drug IM or subcutaneously into anterolateral aspect of thigh; repeat every 5 to 10 minutes as needed
  • Maximum dose per injection: 0.3 mg (0.3 mL)
30 kg or greater: 0.3 to 0.5 mg (0.3 to 0.5 mL) of undiluted drug IM or subcutaneously into anterolateral aspect of the thigh; repeat every 5 to 10 minutes as needed
  • Maximum dose per injection: 0.5 mg (0.5 mL)

Comments:
  • For IM administration, use a long enough needle (at least 1/2 inch to 5/8 inch) to ensure injection into the muscle.
  • Repeated injections should not be administered at the same site as resulting vasoconstriction may cause tissue necrosis.
  • The patient should be monitored clinically for reaction severity and cardiac effects with repeat doses titrated to effect.

Injectable Solution of 0.1 mg/mL (1:10,000):
  • Neonate: 0.01 mg/kg IV slowly once
  • Infant: 0.05 mg IV slowly once; may repeat at 20 to 30 minute intervals as needed

Uses: For the emergency treatment of allergic reactions (Type I) including anaphylaxis to stinging or biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis; and for immediate administration in patients who are determined to be at increased risk for anaphylaxis, including those with a history of anaphylactic reactions

Usual Pediatric Dose for Asthma - Acute

Injectable Solution of 0.1 mg/mL (1:10,000):

  • Neonate: 0.01 mg/kg IV slowly once
  • Infant: 0.05 mg IV slowly once; may repeat at 20 to 30 minute intervals as needed

Use: For the treatment of acute asthmatic attacks to relieve bronchospasm not controlled by inhalation or subcutaneous administration of other solutions of the drug

Usual Pediatric Dose for Pupillary Dilation

Injectable Solution of 1 mg/mL (1:1000):

  • Intraocular: Dilute 1 mL of the 1 mg/mL single-use vial (1:1000) in 100 to 1000 mL of an ophthalmic irrigation fluid to a concentration of 1:100,000 to 1:1,000,000 (10 mcg/mL to 1 mcg/mL) and use the irrigating solution as needed for the surgical procedure
  • Intracameral: Following dilution in an ophthalmic irrigating fluid, the solution may also be injected intracamerally as a bolus dose of 0.1 mL at a dilution of 1:100,000 to 1:400,000 (10 mcg/mL to 2.5 mcg/mL)

Comments:
  • The Adrenalin(R) formulation is not for ophthalmic use.
  • Do not use if the solution is colored, cloudy, or contains particulate matter.

Use: For the induction and maintenance of mydriasis during intraocular surgery

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

Elderly patients may be particularly sensitive to the effects of this drug. Infuse slowly as there is an increased risk for adverse reactions in this patient population; consider lower starting doses for the treatment of anaphylaxis.

Precautions

CONTRAINDICATIONS: None

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration Advice:

  • The specific manufacturer information for the auto-injector chosen should be consulted as not all auto-injectors function the same way nor have the same doses available.
  • Consult specific manufacturer product information for administration instructions.
  • Auto-injector: For single use only; inspect for particulate matter and discoloration; insert IM or subcutaneously into the anterolateral aspect of the thigh, through clothing if necessary; if the patient is a child, hold the leg firmly in place to limit movement prior to and during injection.
  • Adrenalin(R): Not for ophthalmic use.
  • Inspect visually for particulate matter and discoloration prior to administration, whenever solution and container permit; do not use if solution is colored, cloudy, or contains particulate matter.

Storage requirements:
  • Auto-injector: Store in outer case provided to protect from light; store at room temperature; do not refrigerate.
  • Injectable Solution: Protect from light and freezing; store at room temperature; multiple-use vial must be discarded 30 days after initial use.
  • Ampule: Store at room temperature; protect from light, freezing, and alkalis and oxidizing agents.

Reconstitution/preparation techniques:
  • The manufacturer product information should be consulted.

Patient advice:
  • There is a possibility of recurrence of anaphylaxis symptoms after a good response to initial treatment; obtain medical attention following use of this drug.
  • Consult patient information leaflet for further advice.

Frequently asked questions

  • Norepinephrine vs epinephrine: what's the difference?
  • Can you bring an EpiPen on a plane?
  • Can you use an expired EpiPen in an emergency?
  • What's the mechanism of action for epinephrine?
  • What is Neffy?
Share this Article
Latest News
Medical News

Obesity, unhealthy lifestyles may cause heart to age by 5–45 years

May 08, 2025
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Heart disease: Just 3 minutes of 'incidental activity' may lower...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by